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Abstract
Malignant mesothelioma (MM), a rare form of cancer is often associated with previous exposure to fibrous minerals, such as
asbestos. Asbestos exposure increases HER1-activity and expression in pre-clinical models. Additionally, HER1 over-
expression is observed in the majority of MM cases. In this study, the utility of HER1-targeted chimeric IgG1, cetuximab, and
a human IgG2, panitumumab, radiolabeled with
86Y, were evaluated for PET imaging to detect MM non-invasively in vivo,
and to select an antibody candidate for radioimmunotherapy (RIT).
Methods: Radioimmunoconjugates (RICs) of cetuximab and panitumumab were prepared by conjugation with CHX-A’’-
DTPA followed by radiolabeling with
86Y. The HER1 expression of NCI-H226, NCI-H2052, NCI-H2452 and MSTO-211H human
mesothelioma cells was characterized by flow cytometry. In vivo biodistribution, pharmacokinetic analysis, and PET imaging
were performed in tumor bearing athymic mice.
Results: In vivo studies demonstrated high HER1 tumor uptake of both RICs. Significant reduction in tumor uptake was
observed in mice co-injected with excess mAb (0.1 mg), demonstrating that uptake in the tumor was receptor specific.
Significant differences were observed in the in vivo characteristics of the RICs. The blood clearance TKa of
86Y-cetuximab
(0.9–1.1 h) was faster than
86Y-panitumumab (2.6–3.1 h). Also, the tumor area under the curve (AUC) to liver AUC ratios of
86Y-panitumumab were 1.5 to 2.5 times greater than
86Y-cetuximab as observed by the differences in PET tumor to
background ratios, which could be critical when imaging orthotopic tumors and concerns regarding radiation doses to
normal organs such as the liver.
Conclusion: This study demonstrates the more favorable HER1-targeting characteristics of
86Y-panitumumab than
86Y-
cetuximab for non-invasive assessment of the HER1 status of MM by PET imaging. Due to lower liver uptake, panitumumab
based immunoconjugates may fare better in therapy than corresponding cetuximab based immunoconjugates.
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Introduction
Asbestos-related deaths have increased 400 percent in the past
20 years and the number of cases continues to increase despite
awareness of asbestos-related hazards [1,2]. Asbestos is a human
mutagen and carcinogen, responsible for many pulmonary
diseases including asbestosis, bronchogenic carcinoma, and
malignant mesothelioma [2]. Malignant mesothelioma (MM) is a
rare form of an aggressive and often treatment-resistant cancer [3].
Occupational exposure to asbestos is implicated in 70–80% of all
MM. After initial diagnosis, MM has a median survival of 10–18
months [3,4]. Conventional therapies, such as surgery, radiother-
apy, and chemotherapy, do not necessarily improve overall
survival. On the other hand, tremendous advances have been
made regarding understanding the molecular biology of MM.
Understanding the molecular biological features of asbestos-
induced MM is of critical importance. MM cells arise from the
pleura or the peritoneal cavity and produce numerous growth
factors, including epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), and transforming growth factor b (TGF-b)
[3,5,6]. EGF is a potent mitogen for human mesothelial cells. In
normal and pre-malignant animal cells of similar type, exposure to
asbestos leads to autophosphorylation, increased expression of the
cell surface EGF receptor (HER1) that then appears to initiate cell
signaling cascades important in asbestos-induced mitogenesis and
carcinogenesis [7,8,9].
Recent clinical studies have also shown over-expression of
HER1 in MM [10,11,12,13]. In an immunohistochemical (IHC)
and molecular study with clinico-pathological correlations, a
statistically significant correlation was observed between the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18198expression of HER1 by IHC and corresponding mRNA levels.
Secondly, HER1 mRNA levels were higher in tumor specimens
than non-neoplastic pleura samples [14]. In another study
comprising 71 patients, high HER1 expression was detected in
74.6% of the cases; 52.1% cases were positive for HER1 gene
amplification and 45% of the cases had elevated serum HER1
[10]. In that same study, elevated serum and tissue HER1 was
significantly associated with advanced disease stage, suggesting an
important role of EGFR over-expression in mesothelioma
[10,11,12,13].
Based on the findings that HER1 is over-expressed in MM,
HER1-tyrosine kinase inhibitors (TKIs) such as gefinitib and
erlotinib were investigated for therapy of MM patients [15,16]. In
the study utilizing gefinitib, 97% of the patients with MM were
found to have presented with disease that over-expressed HER1,
the gefitinib therapy, however, was ineffective and HER1
expression did not correlate with failure-free survival [16].
Similarly, single agent erlotinib therapy was ineffective in MM,
despite high expression of HER1. The authors speculated that the
activation of the ERK and phosphatidylinositol 3-kinase/Akt
downstream pathways as possible resistance mechanisms to
erlotinib [15].
Since the majority of MMs over-express HER1, this target
might prove suitable for molecular imaging and, ultimately,
targeted radionuclide therapy of MM. Targeted radionuclide
therapy and radioimmunotherapy (RIT) are at the forefront of
molecular cancer treatment modalities that involve the use of
cancer cell targeting radiopharmaceuticals, such as radiolabeled
antibodies, which selectively target certain tumor cells [17,18].
90Y
is one of the very promising radionuclides used for radio-
immunotherapy of hematologic malignancies and solid tumors
[19,20,21] Such radionuclide therapy outcomes will be indepen-
dent of mutations in HER1 or KRAS domains and therefore
overcome the existing limitations of conventional HER1-targeted
therapy. However, since
90Y is a pure ß
2-emitter, its biodistribu-
tion cannot be readily imaged for patient-specific dosimetry which
is essential for pre-therapeutic treatment planning and accurate
absorbed dose estimation in individual patients to mitigate
radiation risks.
111In and
89Zr were used as surrogate PET
radionuclides for
90Y, however disparities were observed in the
biodistribution of these and
90Y labeled antibodies [22,23]. In
recent years,
86Y has gained popularity as an attractive surrogate
for studying
90Y due to its half-life (14. 7 h) and positron emission
which allows quantitative imaging over 2–3 days [24]. Since the
chemical form is identical to
90Y,
86Y labeled antibodies have
identical biodistribution to
90Y labeled antibodies, and therefore
should enable more accurate absorbed dose estimates for
90Y [25].
Based on the previous experiences with
64Cu (half-life =12. 7 h)
labeled antibodies in patients it is anticipated that between 0.18–
0.37 GBq of the injected
86Y labeled antibody will result in useful
quantitative images up to 2–3 d after injection [26,27]. Therefore,
in this study we sought to explore the utility of HER1-targeting
86Y-labeled cetuximab and panitumumab for PET imaging of
MM, to assess HER1 status, and as a means to select and screen
subjects for HER1-targeted radioimmunotherapy (RIT) with
radionuclides such as
90Y for larger tumors or a-emitting
radionuclides such as
212Pb for micrometastatic disease
[28,29,30,31].
In the present study, the in vitro characterization of four
established MM cell lines for HER1 expression is described. Also
detailed are the in vivo targeting characteristics of
86Y-labeled
panitumumab and cetuximab in three human MM tumor
xenograft models in mice for potential use in risk stratification
and quantitative non-invasive imaging of HER1, and assessment
of mAb uptake in MM. In addition to the development of a
potential PET imaging agent, another objective of the studies
described herein was the selection of a preferred antibody
candidate for future RIT studies.
Results
In vitro evaluations
Flow cytometric analysis. Flow cytometric analysis revealed
varied levels of HER1-expression for the mesothelioma cell lines
evaluated (Table S1). NCI-H226 had the highest mean
fluorescence intensity (MFI), whereas NCI-H2452 had the lowest
MFI (Table S1). Panitumumab and cetuximab demonstrated
comparable in vitro binding characteristics for each cell type, as
evidenced by the percentage of cells stained with each of the mAb.
Radiochemistry. The
86Y labeled RICs were successfully
prepared with radiochemical yields ranging from 60-75%, specific
activity exceeding 2 GBq/mg, and with acceptable in vitro
receptor-specificity as previously described [29,30].
In vivo evaluations
Biodistribution studies. In mice bearing the NCI-H226
tumor xenograft, significant decreases in the blood pool activity
was observed over a 4 d time period for both RICs (Table 1). For
86Y-CHX-A’’-DTPA-panitumumab, the blood % ID/g decreased
from 12.0661.28 at 1 d to 6.9461.09% ID/g at 4 d, a 43%
decrease.
86Y-CHX-A’’-DTPA-cetuximab showed an even greater
decrease beginning with a blood %ID/g of 11.7061.44% ID/g at
1 d and ending with 3.4060.60% ID/g at 4 d injection, 29% of
the initial level. Meanwhile, the tumor uptake increased over a 4 d
time period for both RICs (Table 1). The tumor %ID/g of
86Y-
CHX-A’’-DTPA-panitumumab, was 23.1363.36 at 1 d which
increased to 33.1861.84 at 4 d; similarly for
86Y-CHX-A’’-
DTPA-cetuximab, the tumor %ID/g was 21.2461.90% ID/g at 1
d and increased to 28.9363.35 4 d post-injection. The
86Y-CHX-
A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab
uptake in all the three tumor models was HER1-mediated as
demonstrated by receptor-blocking experiments performed by co-
injecting 0.1 mg of the corresponding unlabeled mAb (Fig. 1). In
mice bearing NCI-H226 (Fig. 1A), MSTO-211H (Fig. 1B) or NCI-
2052 (Fig. 1C) tumors, the tumor % ID/g at 3 d was 36.562.1,
23.460.9 and 18.261.8, respectively, after i.v. injection of
86Y-
CHX-A’’-DTPA-panitumumab. The corresponding tumor % ID/
g in mice co-injected with 0.1 mg of panitumumab was 14.161.1,
12.761.0 and 8.360.8, respectively, at the same time point,
thus demonstrating specificity of the
86Y-CHX-A’’-DTPA-
panitumumab. Similarly, for
86Y-CHX-A’’-DTPA-cetuximab,
the tumor % ID/g at 3 d was 29.462.5, 22.866.2 and
19.161.9, respectively, and the corresponding tumor % ID/g in
mice co-injected with 0.1 mg of cetuximab was 8.260.7, 10.062.3
and 9.260.3, respectively, at the same time point. The values were
significantly different (p ,0.05) between unblocked and blocked
groups for each tumor type and for both RICs. Although both
RICs demonstrated HER1-mediated targeting characteristics,
subtle and noteworthy differences in organ uptake were
observed at different time points after the injection (Table 1). At
1 and 2 d after injection, the liver uptake of
86Y-CHX-A’’-DTPA-
cetuximab was significantly greater (p=0.007 and 0.040 at 1 and 2
d, respectively) than the liver uptake of
86Y-CHX-A’’-DTPA-
panitumumab in the same tumor model (Table 1). However, at 4 d
after injection, the blood, spleen, kidney, lung and heart uptake of
86Y-CHX-A’’-DTPA-panitumumab was significantly greater than
the uptake of
86Y-CHX-A’’-DTPA-cetuximab in those organs in
the same tumor model (Table 1). Inter-tumor differences were
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86Y-CHX-A’’-DTPA-
panitumumab was greater in mice bearing NCI-H226 tumors
than in mice bearing MSTO-211H tumors; however, the same
phenomenon was not observed with
86Y-CHX-A’’-DTPA-
cetuximab (Fig. 2A and B).
PET imaging studies and pharmacokinetic analysis.
Small animal PET imaging studies were performed in female
athymic mice bearing NCI-H226, MSTO-211H and NCI-
H2052 tumor xenografts injected with 1.7–1.9 MBq of RIC or
RIC co-injected with 0.1 mg excess of the corresponding mAb
(Figure 2). Tumors were clearly visualized in maximum intensity
projections of miceimagedfrom0.5 to3 dafter injection of either
of the RICs. The tumor-to-background ratios improved over the
period primarily due to the decrease and clearance of the
radioactivity in blood, liver a n db a c k g r o u n dw h i l et h et u m o r
uptake increased. In contrast, when 0.1 mg of excess mAb was
co-injected with its corresponding RIC, tumors were poorly
visualized due to receptor-specific blockage, demonstrating the
HER1-specificity of both radioimmunoconjugates also shown in
quantitative information obtained from PET studies (Figure 3).
Significant differences were found between the liver uptake of
mice injected with
86Y-CHX-A’’-DTPA-panitumumab and mice
injectedwith
86Y-CHX-A’’-DTPA-cetuximab, particularly inthe
NCI-H226 and MSTO-211H tumor models. The liver clearance
of the
86Y-CHX-A’’-DTPA-cetuximab was slower than that of
86Y-CHX-A’’-DTPA-panitumumab therefore resulting in lower
tumor-liver ratios than
86Y-CHX-A’’-DTPA-panitumumab.
Pharmacokinetic analyses performed on biodistribution and
PET derived values, and from values obtained from serial blood
sampling revealed further differences between
86Y-CHX-A’’-
DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab
(Table 2). The blood TKa for
86Y-CHX-A’’-DTPA-panitumumab
was significantly slower than that of
86Y-CHX-A’’-DTPA-
cetuximab; however, no significant difference was observed
between the two RICs in the TKb phase. The
86Y-CHX-A’’-
DTPA-panitumumab blood AUC[0R4] values were slightly greater
than
86Y-CHX-A’’-DTPA-cetuximab values, however the differ-
ence was not statistically significant. For both RICs, the tumor
AUC[0R4] value were highest for mice bearing NCI-H266 tumor
xenografts and lowest for mice bearing NCI-H2052 tumor
xenografts (Table 2). For each tumor model, the
86Y-CHX-A’’-
DTPA-cetuximab liver AUC[0R4] values were significantly greater
than that of
86Y-CHX-A’’-DTPA-panitumumab. The
86Y-CHX-
A’’-DTPA-panitumumab tumor AUC[0R4]: liver AUC[0R4] ratio
values were 1.7, 2.5 and 1.4 times greater than values obtained
from
86Y-CHX-A’’-DTPA-cetuximab in mice bearing NCI-H226,
MSTO-211H and NCI-H2052, respectively (Table 2). The mean
residence times were identical for all of the tumor models and
RICs. For both RICs, PET derived tumor AUC[0R3] values were
significantly greater than corresponding tumor AUC[0R3] values
derived from blocking experiments with 0.1 mg excess mAb co-
injection (Table 2 and Figure 3), thus again demonstrating HER1-
mediated tumor accumulation over the 3 d study period. The
organ uptake values quantified by PET were closely related
(r
2=0.92, p=0.90, n=76) to values determined by ex vivo
biodistribution studies.
Discussion
Information available from the Surveillance, Epidemiology
and End Results (SEER) confirms that the incidence of
mesothelioma has increased in recent years from almost nil to
the current 2500–3000 cases per year in the USA [1]. Diagnosis
of MM is difficult and current treatments do not provide
significant improvements in survival. Computed Tomography
(CT) has been widely used as the primary imaging modality for
the diagnosis, staging, and monitoring of therapeutic response
in MM. More recently, MRI and PET imaging with FDG have
gained popularity for imaging MM because of the excellent
resolution and superiority in the differentiation of malignant
from benign disease [32,33,34]. A prospective study comprising
32 patients, 19 with malignant and 13 with benign disease,
found that FDG PET had a high negative predictive value of
92%. FDG PET imaging showed an absence of FDG uptake,
and correctly classified 31/35 benign lesions. Nevertheless, the
usefulness of FDG is limited by its uptake in inflammatory cells
such as macrophages and activated lymphocytes, which can
cause false-positive results as seen in cases of parapneumonic
effusion, tuberculous and uraemic pleural disease [35,36]. In
spite of recent advances in the diagnosis of MM, therapeutic
Table 1. Biodistribution of
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab.
Organs 1 d 2 d 3 d 4 d
Panitumumab Cetuximab Panitumumab Cetuximab Panitumumab Cetuximab Panitumumab Cetuximab
Blood 12.0661.26 11.7061.44 8.5961.62 8.1660.88 7.5560.92 5.6660.99 6.9461.09 3.4060.60
#
Tumor 23.1363.36 21.2461.90 27.2362.18 24.6961.99 36.5562.04 29.4362.53 33.1861.84 28.9363.35
Liver 7.3860.83 13.1561.21
# 6.6460.61 9.5360.93
# 6.3560.82 8.7760.91 5.0460.32 5.9060.82
Spleen 4.6961.04 3.9660.51 4.7560.68 3.8060.49 4.0560.02 3.5860.59 4.2260.28 1.4860.25
#
Kidney 3.4560.71 3.6160.46 2.5860.18 2.5560.21 2.6960.56 3.0660.16 2.3560.18 1.5360.15
#
Lungs 5.9661.39 5.1260.35 5.0362.40 3.0860.23 5.6760.79 4.2560.50 4.4560.17 1.9260.36
#
Heart 3.5560.76 3.7560.27 2.2960.39 1.9660.12 2.8160.41 2.5060.09 2.4560.16 1.2460.14
#
Muscle 1.7560.21 1.5460.07 1.6060.58 1.0260.13 1.1160.07 1.3460.19 1.0060.13 0.6360.11
Femur 2.7560.18 3.0460.25 2.5160.54 2.4360.13 2.8560.20 2.9760.76 2.5260.23 2.7060.55
Tail 2.1260.42 2.1060.05 1.4960.54 2.2760.24 1.5960.27 2.0560.14 2.1160.18 1.8460.29
In vivo biodistribution of
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab injected i.v. via tail vein of female athymic (NCr) nu/nu mice bearing NCI-
H226 tumor xenograft. Biodistribution data were obtained at 1, 2, 3 and 4 d after injection. All values are expressed as % ID/g. Data represents the mean value 6 SEM
from at least four determinations.
#Values obtained from
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab were significantly different from each other (p,0.05).
doi:10.1371/journal.pone.0018198.t001
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adjuvant radiation therapy remain the mainstay of treatment
for patients with resectable MM [37].
Occupational exposure to asbestos remains the major risk factor
for MM. This exposure has been demonstrated to be associated
with increased HER1 activation and expression [7,8,9]. There-
fore, HER1-targeted imaging can play a complimentary role in a
better understanding of asbestos-induced mesothelioma. While
traditional targeting of HER1 for therapy has not been successful,
it is feasible that HER1 binding molecules could be used as vectors
to effectively deliver imageable or cytotoxic radioactive payloads
differentially to MM cells to potentially improve diagnostic as well
Figure 1. HER1-specificity of
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab. Receptor-meditated uptake of
86Y-
CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab in selected organs of female athymic (NCr) nu/nu mice bearing NCI-H226 (A), MSTO-
211H (B) and NCI-H2052 tumor xenografts (C). Biodistribution data were obtained 3 d after injection. All values are expressed as % ID/g. Data
represent the mean value 6 SEM from at least three determinations.
*Receptor blocking studies were performed by co-injecting 0.1 mg mAb with
the radiotracer. Values obtained from the blocking studies were significantly lower than the unblocked studies (p,0.05) demonstrating receptor-
mediated accumulation in the tumors.
doi:10.1371/journal.pone.0018198.g001
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characteristics of two HER1-binding monoclonal antibodies,
cetuximab and panitumumab, each labeled with
86Y, were
comparatively evaluated as potential diagnostics by PET imaging,
and to select a potential candidate for evaluation in monoclonal
antibody targeted RIT applications.
In vitro HER1 expression was observed in four MM cell lines
evaluated (Table S1) similar to the clinical findings of HER1
over-expression in majority of MM [10,11,12,13]. HER1-
specific tumor targeting was observed in all three xenograft
tumor models evaluated (Figs. 1, 2, and Table 2) supporting the
hypothesis that HER1 targeting can be used for imaging and
radionuclide therapy of MM. Although both radiolabeled
cetuximab and panitumumab demonstrated in vivo HER1-
targeting characteristics, disparities were observed with blood
c l e a r a n c ea n dn o n - t a r g e to r g a nu p t a k e( T a b l e1a n d2 ) .
Cetuximab is a chimeric IgG1 mAb, whereas panitumumab is
af u l l yh u m a nI g G 2 mAb and binds to a different epitope of the
HER1 antigen than cetuximab. Antibodies are usually cleared
through their interaction with the Fc receptors expressed on
cells of the reticuloendothelial system [38,39]. The slower first-
phase blood clearance of
86Y-CHX-A’’-DTPA-panitumumab
may be attributed to the fact that panitumumab is an IgG2
whereas cetuximab is an IgG1.I g G 2 antibodies have lower
affinity and binding to the Fc-gamma receptors than the IgG1
and therefore are cleared more slowly by this mechanism
[38,39]. As observed in the biodistribution (Table 1) and PET
imaging studies (Fig. 2 and Table 2), the liver uptake and
accumulation of
86Y- CHX-A’’-DTPA-cetuximab was signifi-
cantly greater than that of
86Y- CHX-A’’-DTPA-panitumumab
in all three xenograft tumor models, and as a result, tumor to
liver ratios were better for
86Y- CHX-A’’-DTPA-panitumumab
than
86Y- CHX-A’’-DTPA-cetuximab (Table 2). For
90Y- RIT,
the data obtained from this pre-clinical study indicate that RIT
with
90Y- CHX-A’’-DTPA-cetuximab and
90Y- CHX-A’’-
DTPA-panitumumab will result in similar tumor accumulation;
however, that same data also suggests that
90Y- CHX-A’’-
DTPA-cetuximab will result in higher radiation doses to the
liverthan
90Y- CHX-A’’-DTPA-panitumumab due significantly
greater cumulative activity in liver (presented as AUC in
table 2). Therefore,
90Y- CHX-A’’-DTPA-panitumumab may
be a more favorable candidate for RIT than
90Y- CHX-A’’-
DTPA-cetuximab due to higher tumor:liver that may result in
lower radiation doses to the normal organs than
90Y- CHX-A’’-
DTPA-cetuximab. Previous clinical study with
111In labeled
225 (murine version of cetuximab) suggests the presence of
HER1 receptor in the liver based on the dose-dependent liver
uptake and clearance of the
111In labeled murine 225. However,
a study performed with radiolabeled chimeric mAb, C225
(cetuximab) concluded that the residence time in the liver
Figure 2. PET imaging of mesothelioma with
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab. Representative
reconstructed and processed maximum intensity projections of female athymic (NCr) nu/nu mouse bearing NCI-226, MSTO-211H and NCI-H2052
tumor xenografts. Mice represented in the images were injected i.v. via the tail vein with 1.7–1.9 MBq/,5 mg of the radioimmunoconjugate or co-
injected with 0.1 mg excess mAb. The scale represents % maximum and minimum threshold intensity.
*Receptor blocking studies were performed by
co-injecting 0.1 mg excess mAb with the corresponding radioimmunoconjugate.
doi:10.1371/journal.pone.0018198.g002
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without. One explanation could indeed be that the liver does
not have C225 binding sites, but simply metabolically extracts
whatever is not taken up elsewhere in the body. In the pre-
clinical study performed in the report, the uptake in liver was
not blocked by co-injecting excess cetuximab and panitumu-
mab, suggesting the lack of cetuximab and panitumumab
binding sites in mouse liver, which in part concurs with the
information provided by the manufacturer of cetuximab,
ImClone Systems. Therefore, the differences in liver zzzuptake
may be a function of radiometabolities and/or Fc-gamma
interactions of cetuximab and panitumumab. These differences
can also have a significant impact for targeting intrapleural and
intraperitoneal MM with respect to signal to noise ratios as well
as radiation doses delivered to the liver, particularly in the
setting of radionuclide therapy.
For this reason, panitumumab presents as a better alternative
than cetuximab for HER1-targeted imaging and RIT. The
HER1- targeting characteristics of radiolabeled panitumumab
shown here points to its potential as a great diagnostic tool for
detection and staging of MM. The results also point to the
potential of panitumumab as a vehicle for delivering therapeutic
radioactivity to HER1-expressing MM tumors. This approach to
MM therapy should improve outcomes for HER1 over-expressing
tumors that have not responded to classical HER1 therapy with
TKIs and monoclonal antibodies due to resistance.
Figure 3. Time-activity curves obtained from quantitative PET imaging of mesothelioma with
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab. PET generated time-activity curves in mice bearing (A) NCI-H226, (B) MSTO-211H and (C) NCI-H2052 tumor
xenografts.
*Receptor blocking studies were performed by co-injecting 0.1 mg excess mAb with the corresponding radioimmunoconjugate.
doi:10.1371/journal.pone.0018198.g003
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In this study, the more favorable HER1-targeting characteristics
of
86Y- CHX-A’’-DTPA-panitumumab than
86Y- CHX-A’’-
DTPA-cetuximab for non-invasive staging and assessment of the
HER1 status of MM has been demonstrated. HER1-targeted
immunoPET can be complimentary to CT and MRI for diagnosis
and prognosis of MM. Valuable molecular information on further
understanding the role of HER1 in asbestos-induced MM may also
be garnered. In conclusion, the strategy to target asbestos-induced
HER1 over-expression for molecular imaging and radionuclide
therapy warrants further investigation for clinical translation and
improved clinical outcomes and management of MM.
Materials and Methods
Cell lines and tissue culture
NCI-H226, NCI-H2052, NCI-H2452 and MSTO-211H human
mesothelioma cells were purchased from American Type Culture
Collection (Manassas, VA). All cell lines were grown as a monolayer
at 37uC, in a humidified atmosphere of 5% CO2 and 95% air. Cells
were cultured in RPMI-1640 media containing 2 mM L-glutamine,
10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and
1.5 g/L sodium bicarbonate. All media were additionally supple-
mented with 10% FetalPlex (Gemini Bio-Products, Inc, Woodland,
CA, USA). Media and supplements were obtained from Invitrogen
(Carlsbad, CA, USA) and Lonza (Walkersville, MD, USA).
Flow-Cytometric Analysis
HER1 expression of the mesothelioma cell lines was evaluated by
standard flow-cytometric techniques [40]. Briefly, cells were
trypsinized, pelleted at 1,5006g for 10 min and re-suspended in
phosphate-buffered saline (PBS; pH 7.2) containing 1% bovine
serum albumin (BSA). The cells (1610
6 cells in 100 mL of 1% BSA
in PBS) were added to 12675 mM polypropylene tubes (Falcon
Labware, Franklin Lakes, NJ) along with 1 mg of cetuximab
(Erbitux: Bristol-Meyers Squibb Co, Princeton, NJ) or panitumu-
mab (Vectibix: Amgen, Thousand Oaks, CA) in 100 mL. The cells
were incubated for 1 h at 4uC, washed three times by adding 2 mL
of 1% BSA in PBS, pelleting the cells at 1,0006g for 5 min and
decanting the supernatant. Following the last wash, 100 mLo f
FITC-labeled goat anti-human IgG (50 mg/mL; Kirkegaard and
Perry, Gaithersburg, MD) was added to the cells and incubated for
an additional 1 h at 4uC. The cells were washed three times as
before and analyzed (10,000 events) using a FACScalibur (BD
Biosciences, San Jose, CA) with CellQuest software. HuM195, an
anti-CD33 mAb kindly provided by Dr. Michael McDevitt at
MemorialSloan-KetteringCancerCenter,servedasacontrolmAb.
Preparation of radioimmunoconjugates
The
86Y was produced by the previously described
86Sr(p,n)
86Y
reaction using a SrCO3 target [29,41]. The preparation and
quality control of
86Y-CHX-A’’-DTPA-panitumumab and
86Y-
CHX-A’’-DTPA-cetuximab conjugates was performed as previ-
ously described [29,30].
Animal and tumor models
All animal studies were performed in accordance with the NIH
guidelines for the humane use of animals and all procedures were
reviewed and approved by the National Cancer Institute Animal
Table 2. Pharmacokinetic characteristics of
86Y-CHX-A’’-DTPA panitumumab and
86Y-CHX-A’’-DTPA-cetuximab.
Pharmacokinetic
characteristics NCI-H226 MSTO-211H NCI-H2052
86Y labeled antibody Panitumumab Cetuximab Panitumumab Cetixumab Panitumumab Cetuximab
In vitro expression
as MFI (%)
375.4 (99.85) 345.4 (99.7) 217.2 (87.2) 224.4 (79.9) 330.5 (93.0) 337.5 (90.3)
Blood clearance (h) a-t 1/2=3.161.4
b-t 1/2=62.1616.1
a-t 1/2=0.960.2
#
b-t 1/2=43.5611.5
a-t 1/2=3.060.9
b-t 1/2=58.1610.2
a-t 1/2=1.160.1
#
b-t 1/2=47.8611.9
a-t 1/2=2.661.2
b-t 1/2=86.9624.3
a-t 1/2=0.960.3
#
b-t 1/2=46.169.8
Blood AUC[0R4]
(%ID
.d
.g
21)
26.661.5 21.762.3 30.362.1 29.761.9 30.361.8 29.763.1
Tumor AUC[0R4]
(%ID
.d
.g
21)
105.765.8 90.468.2 69.868.5 63.064.2 60.663.4 58.662.9
Liver AUC[0R4]
(%ID
.d
.g
21)
24.261.2 35.163.2
# 18.261.1 40.663.3
# 29.762.1 40.763.4
#
Tumor PET AUC[0R3]
(%ID
.d
.cc
21)
72.364.8 60.765.5 46.965.5 43.763.2 41.263.9 40.662.6
Tumor PET AUC[0R3]
(%ID
.d
.cc
21)*
26.161.2 22.360.4 25.061.2 22.561.0 25.060.9 21.661.1
Tumor AUC[0R4]:
Blood AUC[0R4]
4.0 4.2 2.3 2.1 2.0 2.0
Tumor AUC[0R4]:
Liver AUC[0R4]
4.4 2.6 3.8 1.5 2.0 1.4
Tumor AUMC[0R4]
(%ID
. d
2.g
-1)
253.6616.2 216.8618.4 172.5618.1 151.0611.2 152.368.1 146.469.9
Tumor MRT (d) 2.4 2.4 2.5 2.4 2.5 2.5
Pharmacokinetic characteristics of
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab injected i.v. via tail vein of female athymic (NCr) nu/nu mice
bearing NCI-H226, MSTO-211H and NCI-H2052 tumor xenografts. Data represent the mean values from three to six determinations.
*Receptor blocking studies were performed by co-injecting 0.1 mg mAb with the radiotracer. Values obtained from the blocking studies were significantly lower than
the unblocked studies (p,0.05) demonstrating receptor-mediated accumulation in the tumors.
#Values obtained from
86Y-CHX-A’’-DTPA-panitumumab and
86Y-CHX-A’’-DTPA-cetuximab were significantly different from each other (p,0.05).
doi:10.1371/journal.pone.0018198.t002
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5–8 week old female athymic nu/nu mice (Charles River
Laboratory, Wilmington, DE) were injected subcutaneously with
2–4610
6 MSTO-211H, 6–10610
6 NCI-H226, or 6–10610
6
NCI-H2052 cells in 200 mL medium containing 20% matrigel.
Biodistribution and pharmacokinetic studies
Tumor bearing female athymic mice were intravenously (i.v.)
injected with 0.4–0.6 MBq (,5 mg) of
86Y-CHX-A’’-DTPA-
cetuximab or
86Y-CHX-A’’-DTPA-panitumumab. To demon-
strate HER1-specificity, excess mAb (0.1 mg) was co-injected with
the corresponding radioimmunoconjugate (RIC) into an addition-
al set of mice bearing each of the tumor xenografts. At the desired
time points, the animals were sacrificed by CO2 inhalation.
Tumor, blood and selected organs were harvested, wet-weighed,
and the radioactivity measured in a Wizard 1480 gamma counter
(PerkinElmer, Shelton, CT). The percent injected dose per gram
(% ID/g) of tissue was calculated by comparison with standards
representing 10% of the injected dose per animal. Non-
compartmental pharmacokinetics was performed to determine
area under the curve (AUC), area under the first moment curve
(AUMC) and the mean residence time (MRT) using trapezoidal
integration analysis [42]. The sample size for biodistribution study
was equal to or greater than four animals per group.
PET imaging studies
Small animal PET studies were performed using the ATLAS
(Advanced Technology Laboratory Animal Scanner) at the
National Institutes of Health, Bethesda, MD, USA. Whole body
imaging studies (6 bed positions, total acquisition time of 1 h per
mouse) were carried out on mice anesthetized with 1.5–1.7%
isoflurane on a temperature-controlled bed as previously described
[29]. Tumor bearing female athymic mice were injected i.v. with
1.7–1.9 MBq (,5 mg) of
86Y-CHX-A’’-DTPA-cetuximab or
86Y-
CHX-A’’-DTPA-panitumumab. To determine HER1-specificity,
excess unmodified mAb (0.1 mg) was co-injected with the
corresponding RIC. Phantom studies, image acquisition, process-
ing and analysis was performed as previously described [29]. After
imaging, the mice were euthanized and biodistribution studies
were performed to determine the correlation between PET-
assessed in vivo % ID/cm
3 and biodistribution determined ex vivo %
ID/g. The sample size for PET imaging study was equal to or
greater than three animals per group.
Statistical Analysis
All numerical data were expressed as the mean of the values 6
the standard error of mean (SEM). Graphpad Prism version 5 (San
Diego, CA, USA) was used for statistical analysis. A p value less
than 0.05 was considered statistically significant.
Supporting Information
Table S1 Relative in vitro expression of HER1 in human
mesothelioma cells determined by FACS based assay. MFI =
mean fluorescence intensity.
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